Evaluating the Effect of Melatonin on Positive and Negative Symptoms of Schizophrenic Patients: A Randomized Placebo-Controlled Study.

Forouzan Behrouzian, Leila Abdi, Masoumeh Nazarinasab, Amirali Moghaddam Sadegh, Sanam Anoosheh, Maryam Moradi
{"title":"Evaluating the Effect of Melatonin on Positive and Negative Symptoms of Schizophrenic Patients: A Randomized Placebo-Controlled Study.","authors":"Forouzan Behrouzian,&nbsp;Leila Abdi,&nbsp;Masoumeh Nazarinasab,&nbsp;Amirali Moghaddam Sadegh,&nbsp;Sanam Anoosheh,&nbsp;Maryam Moradi","doi":"10.18502/ijps.v18i2.12362","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> Schizophrenia is known as a severe psychiatric disorder with a broad range of clinical indications and symptoms such as positive and negative symptoms. This study was conducted with the aim of investigating the effect of melatonin on positive and negative symptoms of inpatients with schizophrenia. <b>Method</b> <b>:</b> This study was conducted as a randomized placebo-controlled trial (double-blind) in the population of patients with schizophrenia. Study samples were selected from inpatients with schizophrenia, according to the DSM-5 criteria, who had not been diagnosed with a depressive episode of schizophrenia based on the Calgary questionnaire and who also met the inclusion criteria. 46 patients with schizophrenia were randomly assigned to the intervention (6 mg melatonin per day as two 3 mg pills for six weeks) and placebo groups. The positive and negative symptom scale (PANSS) was used to assess the effect of treatment at T1 (before intervention), T2 (three weeks after beginning the intervention) and T3 (six weeks after beginning the intervention). To check the research hypotheses, multiple comparison statistics were used by the SPSS 22 software. <b>Results:</b> The placebo and melatonin groups had no significant difference in terms of PANSS scores (negative, positive, general and total symptom scores) at T1. Also, there was no difference in PANSS scores between the two groups at T2. However, at T3, there was a significant difference between the two groups only in the score of negative symptoms of PANSS (P = 0.036), so that negative symptoms of schizophrenia were significantly reduced in the intervention group compared to the placebo group. Furthermore, based on within-group analyzes, all PANSS scores were significantly reduced in the two groups at T2 and T3 (P < 0.05). <b>Conclusion:</b> Long-term use (at least six weeks) of melatonin can improve the negative symptoms of schizophrenia. Since antipsychotics can better affect the positive symptoms, the use of melatonin in combination with these drugs may perhaps further improve the patients' symptoms.</p>","PeriodicalId":38866,"journal":{"name":"Iranian Journal of Psychiatry","volume":"18 2","pages":"119-126"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c0/39/IJPS-18-119.PMC10293691.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijps.v18i2.12362","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Schizophrenia is known as a severe psychiatric disorder with a broad range of clinical indications and symptoms such as positive and negative symptoms. This study was conducted with the aim of investigating the effect of melatonin on positive and negative symptoms of inpatients with schizophrenia. Method : This study was conducted as a randomized placebo-controlled trial (double-blind) in the population of patients with schizophrenia. Study samples were selected from inpatients with schizophrenia, according to the DSM-5 criteria, who had not been diagnosed with a depressive episode of schizophrenia based on the Calgary questionnaire and who also met the inclusion criteria. 46 patients with schizophrenia were randomly assigned to the intervention (6 mg melatonin per day as two 3 mg pills for six weeks) and placebo groups. The positive and negative symptom scale (PANSS) was used to assess the effect of treatment at T1 (before intervention), T2 (three weeks after beginning the intervention) and T3 (six weeks after beginning the intervention). To check the research hypotheses, multiple comparison statistics were used by the SPSS 22 software. Results: The placebo and melatonin groups had no significant difference in terms of PANSS scores (negative, positive, general and total symptom scores) at T1. Also, there was no difference in PANSS scores between the two groups at T2. However, at T3, there was a significant difference between the two groups only in the score of negative symptoms of PANSS (P = 0.036), so that negative symptoms of schizophrenia were significantly reduced in the intervention group compared to the placebo group. Furthermore, based on within-group analyzes, all PANSS scores were significantly reduced in the two groups at T2 and T3 (P < 0.05). Conclusion: Long-term use (at least six weeks) of melatonin can improve the negative symptoms of schizophrenia. Since antipsychotics can better affect the positive symptoms, the use of melatonin in combination with these drugs may perhaps further improve the patients' symptoms.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估褪黑素对精神分裂症患者阳性和阴性症状的影响:一项随机安慰剂对照研究
目的:精神分裂症是一种严重的精神疾病,具有广泛的临床适应症和症状,如阳性和阴性症状。本研究旨在探讨褪黑素对精神分裂症住院患者阳性和阴性症状的影响。方法:本研究在精神分裂症患者群体中进行随机安慰剂对照试验(双盲)。研究样本选自精神分裂症住院患者,根据DSM-5标准,根据卡尔加里问卷未被诊断为精神分裂症抑郁发作,同时符合纳入标准。46名精神分裂症患者被随机分配到干预组(每天6毫克褪黑素,两粒3毫克,持续6周)和安慰剂组。采用阳性和阴性症状量表(PANSS)在T1(干预前)、T2(干预开始后3周)和T3(干预开始后6周)评估治疗效果。为了检验研究假设,采用SPSS 22软件进行多重比较统计。结果:安慰剂组和褪黑素组T1时PANSS评分(阴性、阳性、一般和总症状评分)差异无统计学意义。两组在T2时的PANSS评分也无差异。但在T3时,两组间仅在PANSS阴性症状得分上有显著性差异(P = 0.036),干预组的精神分裂症阴性症状较安慰剂组明显减轻。组内分析显示,两组患者T2、T3时PANSS评分均显著降低(P < 0.05)。结论:长期使用(至少6周)褪黑素可改善精神分裂症的阴性症状。由于抗精神病药物可以更好地影响阳性症状,因此褪黑激素与这些药物联合使用可能会进一步改善患者的症状。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Iranian Journal of Psychiatry
Iranian Journal of Psychiatry Medicine-Psychiatry and Mental Health
CiteScore
4.00
自引率
0.00%
发文量
42
审稿时长
4 weeks
期刊最新文献
A Comparison of Effectiveness of Attention Process Training (APT) with Parenting Management Training (PMT) in Reducing Symptoms of Attention Deficit Hyperactivity Disorder. An Increased Need to Identify Protective Factors for Sexual Assault. Application of Acceptance and Commitment Therapy (ACT) in Children and Adolescents Psychotherapy: An Umbrella Review. Investigating Cortical Complexity in Mixed Dementia through Nonlinear Dynamic Analyses: A Resting-State EEG Study. Psychometric Properties of a Persian Version of the Columbia Suicide Severity Rating Scale (C-SSRS) in Iranian Soldiers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1